Your browser doesn't support javascript.
loading
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev, Harveer; Chiang, Ting-Wei Will; Lescale, Chloe; de Krijger, Inge; Martin, Alistair G; Pilger, Domenic; Coates, Julia; Sczaniecka-Clift, Matylda; Wei, Wenming; Ostermaier, Matthias; Herzog, Mareike; Lam, Jonathan; Shea, Abigail; Demir, Mukerrem; Wu, Qian; Yang, Fengtang; Fu, Beiyuan; Lai, Zhongwu; Balmus, Gabriel; Belotserkovskaya, Rimma; Serra, Violeta; O'Connor, Mark J; Bruna, Alejandra; Beli, Petra; Pellegrini, Luca; Caldas, Carlos; Deriano, Ludovic; Jacobs, Jacqueline J L; Galanty, Yaron; Jackson, Stephen P.
Affiliation
  • Dev H; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Chiang TW; Academic Urology Group, Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
  • Lescale C; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • de Krijger I; Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France.
  • Martin AG; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands.
  • Pilger D; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Coates J; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Sczaniecka-Clift M; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Wei W; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Ostermaier M; Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France.
  • Herzog M; Institute of Molecular Biology (IMB), Mainz, Germany.
  • Lam J; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Shea A; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Demir M; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Wu Q; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Yang F; Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Fu B; Wellcome Trust Sanger Institute, Hinxton, UK.
  • Lai Z; Wellcome Trust Sanger Institute, Hinxton, UK.
  • Balmus G; AstraZeneca, Waltham, MA, USA.
  • Belotserkovskaya R; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Serra V; Wellcome Trust Sanger Institute, Hinxton, UK.
  • O'Connor MJ; The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Bruna A; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Beli P; AstraZeneca, Cambridge, UK.
  • Pellegrini L; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Caldas C; Institute of Molecular Biology (IMB), Mainz, Germany.
  • Deriano L; Department of Biochemistry, University of Cambridge, Cambridge, UK.
  • Jacobs JJL; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Galanty Y; Genome Integrity, Immunity and Cancer Unit, Department of Immunology, Department of Genomes and Genetics, Institut Pasteur, Paris, France. ludovic.deriano@pasteur.fr.
  • Jackson SP; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan , Amsterdam, the Netherlands. j.jacobs@nki.nl.
Nat Cell Biol ; 20(8): 954-965, 2018 08.
Article in En | MEDLINE | ID: mdl-30022119
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Bone Neoplasms / Breast Neoplasms / Proteins / Osteosarcoma / Drug Resistance, Neoplasm / BRCA1 Protein / DNA End-Joining Repair / Recombinational DNA Repair / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Language: En Journal: Nat Cell Biol Year: 2018 Document type: Article Affiliation country: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Bone Neoplasms / Breast Neoplasms / Proteins / Osteosarcoma / Drug Resistance, Neoplasm / BRCA1 Protein / DNA End-Joining Repair / Recombinational DNA Repair / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Language: En Journal: Nat Cell Biol Year: 2018 Document type: Article Affiliation country: Reino Unido